Semaglutide cuts heavy drinking in alcohol use disorder with obesity

This trial provides the first randomised evidence that once-weekly semaglutide 2.4 mg reduces alcohol consumption in treatment-seeking patients with alcohol use disorder and comorbid obesity, expanding the potential role of glucagon-like peptide-1 receptor agonists in addiction pharmacotherapy.

semaglutideGLP-1 receptor agonistalcohol use disorderobesityaddiction medicinerandomised controlled trialheavy drinking daysphosphatidyl ethanolweight loss Behavioral Health / Addiction Medicine

Background Information

Semaglutide reduces alcohol intake in comorbid obesity.

Addressing alcohol use disorder alongside obesity can improve health outcomes; semaglutide may offer dual benefits. Participants receiving semaglutide showed a significant reduction in alcohol consumption and heavy drinking days compared to placebo over 26 weeks. This study supports the potential use of semaglutide for patients with alcohol use disorder and comorbid obesity; however, further research is needed for broader application. Semaglutide may reduce alcohol intake in patients with alcohol use disorder and obesity.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Klausen MK, Justesen SK, Pedersen JN, Rasmussen L, Jensen A, Jensen ME, Knorr UB, Bergmann ML, Holst JJ, Hartmann B, Koob GF, Benveniste H, Volkow ND, Ekstrøm CT, Knudsen GM, Vilsbøll T, Fink-Jensen A

Citation: Klausen MK, Justesen SK, Pedersen JN, et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2026;407(10540):1687-1698. doi:10.1016/S0140-6736(26)00305-3

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →